Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
18.88
Dollar change
+0.67
Percentage change
3.68
%
IndexRUT P/E- EPS (ttm)-4.15 Insider Own47.92% Shs Outstand75.50M Perf Week9.51%
Market Cap1.72B Forward P/E- EPS next Y-4.32 Insider Trans53.14% Shs Float47.32M Perf Month-1.41%
Income-307.00M PEG- EPS next Q-1.01 Inst Own54.44% Short Float16.87% Perf Quarter0.11%
Sales117.00M P/S14.66 EPS this Y7.42% Inst Trans-0.67% Short Ratio9.08 Perf Half Y0.69%
Book/sh6.12 P/B3.09 EPS next Y-12.49% ROA-25.16% Short Interest7.98M Perf Year7.15%
Cash/sh8.35 P/C2.26 EPS next 5Y- ROE-54.87% 52W Range12.95 - 25.47 Perf YTD-1.15%
Dividend Est.- P/FCF- EPS past 5Y-23.70% ROI-53.67% 52W High-25.87% Beta0.80
Dividend TTM- Quick Ratio4.52 Sales past 5Y164.80% Gross Margin86.32% 52W Low45.79% ATR (14)0.97
Dividend Ex-Date- Current Ratio4.52 EPS Y/Y TTM-11.90% Oper. Margin-290.60% RSI (14)57.32 Volatility5.61% 5.33%
Employees577 Debt/Eq0.26 Sales Y/Y TTM4.46% Profit Margin-262.39% Recom1.45 Target Price38.67
Option/ShortYes / Yes LT Debt/Eq0.24 EPS Q/Q-16.23% Payout- Rel Volume0.85 Prev Close18.21
Sales Surprise9.54% EPS Surprise-5.41% Sales Q/Q-7.89% EarningsFeb 21 AMC Avg Volume879.27K Price18.88
SMA204.22% SMA5010.71% SMA2005.41% Trades Volume744,390 Change3.68%
Date Action Analyst Rating Change Price Target Change
Nov-18-22Initiated BofA Securities Neutral $33
Oct-11-22Initiated Morgan Stanley Overweight $40
Oct-15-21Resumed BTIG Research Buy $57
Nov-24-20Initiated Berenberg Buy $50
Nov-23-20Initiated Evercore ISI Outperform
Apr-03-20Initiated Cantor Fitzgerald Overweight $21
Mar-04-20Initiated Barclays Overweight $24
Nov-12-19Initiated SunTrust Buy $20
Sep-27-19Initiated Mizuho Buy $22
May-24-19Resumed Citigroup Buy $25
Mar-26-24 04:35PM
Mar-20-24 07:00PM
Mar-11-24 04:35PM
Feb-29-24 03:14AM
Feb-28-24 04:05PM
04:35PM Loading…
Feb-27-24 04:35PM
Feb-22-24 11:10AM
09:55AM
07:16AM
Feb-21-24 04:37PM
04:05PM
Feb-09-24 04:35PM
Feb-07-24 05:00PM
Feb-05-24 12:59PM
Jan-29-24 05:00PM
04:35PM Loading…
Jan-26-24 04:35PM
Jan-16-24 05:00PM
Dec-11-23 04:35PM
Dec-04-23 08:00AM
Nov-27-23 04:35PM
Nov-14-23 04:00PM
Nov-13-23 04:35PM
Nov-08-23 04:05PM
Nov-07-23 04:01PM
Nov-06-23 05:00PM
Oct-31-23 10:01AM
Oct-24-23 04:35PM
Oct-17-23 04:00PM
Oct-10-23 04:35PM
Sep-27-23 05:14AM
04:35PM Loading…
Sep-26-23 04:35PM
Sep-11-23 04:35PM
Sep-05-23 07:37PM
Aug-24-23 04:35PM
11:30AM
09:02AM
Aug-23-23 11:39AM
09:00AM
Aug-09-23 04:35PM
Aug-07-23 09:15AM
08:00AM
Aug-03-23 05:55PM
Aug-02-23 05:25PM
Aug-01-23 05:45PM
Jul-25-23 04:35PM
Jul-11-23 04:35PM
Jul-03-23 06:50AM
Jun-26-23 04:35PM
Jun-21-23 08:00PM
Jun-12-23 12:08PM
Jun-09-23 04:35PM
Jun-05-23 02:59PM
Jun-03-23 01:30PM
May-30-23 04:00PM
May-26-23 04:05PM
10:27AM
May-24-23 04:35PM
May-17-23 08:30AM
May-16-23 11:51AM
09:31AM
May-15-23 08:30AM
May-11-23 09:44AM
09:33AM
07:44AM
May-09-23 06:15PM
04:05PM
May-08-23 04:35PM
10:04AM
May-05-23 12:45PM
09:17AM
May-04-23 12:04PM
May-03-23 01:47PM
01:20PM
May-01-23 10:00AM
Apr-26-23 08:00PM
Apr-25-23 04:05PM
Apr-19-23 11:17AM
Apr-11-23 04:05PM
Mar-09-23 04:05PM
Mar-06-23 12:33PM
Mar-03-23 02:20PM
Mar-02-23 04:00PM
Feb-28-23 05:35PM
04:05PM
Feb-24-23 04:05PM
Feb-23-23 01:41PM
Feb-17-23 12:24PM
Feb-15-23 10:57AM
07:50AM
Feb-14-23 06:33AM
Feb-09-23 04:05PM
09:48AM
Feb-08-23 10:53AM
Feb-07-23 12:17PM
Feb-06-23 04:05PM
Feb-03-23 02:02PM
Jan-30-23 10:00AM
Jan-25-23 10:21AM
Jan-24-23 04:05PM
Jan-23-23 11:01AM
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jarrett JenniferChief Operating OfficerMar 18 '24Sale17.9213,449240,941226,804Mar 20 04:19 PM
Jarrett JenniferChief Operating OfficerFeb 27 '24Sale20.1134,070685,148240,253Feb 28 07:55 PM
Jaen Juan C.PresidentFeb 27 '24Sale20.1023,132464,9531,188,233Feb 28 07:55 PM
Jarrett JenniferChief Operating OfficerFeb 26 '24Sale20.0724,555492,819274,323Feb 28 07:55 PM
Jaen Juan C.PresidentFeb 26 '24Sale20.063,90078,2341,211,365Feb 28 07:55 PM
GILEAD SCIENCES, INC.10% OwnerJan 29 '24Buy21.0015,238,095319,999,99530,061,124Jan 31 05:00 PM
Jaen Juan C.PresidentJan 02 '24Sale20.096,975140,1281,215,265Jan 04 05:22 PM
Goeltz II Robert C.Chief Financial OfficerJan 02 '24Sale20.002,00440,08051,831Jan 04 05:23 PM
Jarrett JenniferChief Operating OfficerDec 22 '23Sale17.7621,521382,213258,878Dec 26 04:04 PM
Azoy AlexanderChief Accounting OfficerDec 01 '23Sale14.952824,21611,596Dec 05 04:28 PM
Jarrett JenniferChief Operating OfficerSep 22 '23Sale19.9921,369427,166302,691Sep 26 04:35 PM
Jarrett JenniferChief Operating OfficerJul 28 '23Sale20.2545,000911,250336,566Jul 31 04:15 PM
Azoy AlexanderChief Accounting OfficerJul 03 '23Sale20.411,01820,77711,596Jul 05 04:05 PM
GILEAD SCIENCES, INC.10% OwnerJun 28 '23Buy19.261,010,00019,452,60014,823,029Jun 30 03:12 PM
Jarrett JenniferChief Operating OfficerJun 22 '23Sale19.1212,437237,795381,566Jun 26 04:36 PM
Jarrett JenniferChief Operating OfficerJun 16 '23Sale19.3512,563243,094394,003Jun 16 08:16 PM
Goeltz II Robert C.Chief Financial OfficerJun 07 '23Sale20.044,04981,14259,392Jun 09 04:05 PM